5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>Wednesday 11 th September 2013,16h15 – 18h15WORKSHOP 3: “INNATE IMMUNITY AGAINST VIRUSES”KEYNOTE:Chairpersons: Denis GERLIER (Paris, FRANCE) &Maria-Carla SALEH (Paris, FRANCE)Room Gratte-Ciel 1, 2, 3Manipulation <strong>of</strong> autophagy by measles virusMathias FAURECentre de Recherche International en Infectiologie (CIRI), INSERMU1111, UCBL-1, CNRS UMR5308, ENS-Lyon, FRANCEMacroautophagy, referred to as autophagy, is a lysosomal catabolicpathway, which allows the sequestration <strong>of</strong> portions <strong>of</strong> the cytoplasmwithin vesicles called autophagosomes, leading to their ultimate degradationwithin autolysosomes. In mammalian cells, regulation <strong>of</strong> autophagyinvolves dozens <strong>of</strong> proteins including those <strong>of</strong> the ATG (AuTophaGyrelated)family. Essential for the maintenance <strong>of</strong> cellular homeostasis,autophagy is also a cell-autonomous defense mechanism that allows thetargeting <strong>of</strong> pathogens, including viruses, towards lysosomes. In addition,autophagy may potentiate innate and adaptive antiviral immune responses.However, several viruses have evolved strategies in order to escape orhijack autophagy to facilitate their replication.Infection with measles virus leads to a paradox: despite the development<strong>of</strong> an effective immune response, which eliminates the virus and leads tothe development <strong>of</strong> a lifelong immunity, immunosuppression occurs. Wehave shown that CD46, the receptor <strong>of</strong> the attenuated strains <strong>of</strong> measlesvirus, is directly connected to autophagy via a specific molecular pathway.Furthermore, we found that, during infection, two other pathways lead tothe induction <strong>of</strong> autophagy, which are both independent <strong>of</strong> CD46 and fromeach other. These pathways contribute to the ability <strong>of</strong> measles virus toexploit the autophagic process in order to replicate, through the delay <strong>of</strong>virus-induced cell death. Thus, subtle relationships between measles virusand autophagy could contribute to either control the infection or to increaseinfectivity.The antiviral pathogen recognition receptor RIG I is known to bind nakeddsRNA containing a triphosphate (ppp) 5 ′ terminus. It remained unclear,however, whether RIG I can also recognize RNAs packaged into nucleocapsids,the first viral structure to enter the host cell. We show that incomingnucleocapsids <strong>of</strong> viruses containing a 5 ′ ppp dsRNA “panhandle” structuretrigger an antiviral signaling cascade that commences with RIG I and terminateswith activation <strong>of</strong> the transcription factor IRF 3. Independent <strong>of</strong>mammalian c<strong>of</strong>actors or <strong>of</strong> viral polymerase activity, RIG I interacted withthe viral nucleocapsids, underwent a conformational switch, and homooligomerized. Enzymatic probing, as well as super resolution GSDIMmicroscopy (Ground State Depletion Microscopy followed by IndividualMolecule return) suggest that RIG I associates with the 5 ′ ppp panhandlestructure on the viral nucleocapsids.These results define the entry <strong>of</strong> nucleocapsids into the cytoplasm as thefirst RIG I sensitive step in infection, and establish viral nucleocapsids witha5 ′ ppp dsRNA panhandle as a pathogen associated molecular pattern forRIG I (Weber et al., Cell Host and Microbe, 2013).REF 002Sensing <strong>of</strong> infected cells in absence <strong>of</strong> virus particles by plasmacytoiddendritic cells is inhibited by the ribonuclease Erns <strong>of</strong> classical swinefever virusNicolas RUGGLI, Sylvie PYTHON, Markus GERBER, Rolf SUTER,Artur SUMMERFIELDInstitute <strong>of</strong> <strong>Virology</strong> and Immunology, Mittelhäusern, SWITZERLANDPlasmacytoid dendritic cells (pDC) have been shown to sense efficientlyhepatitis C virus infected cells using a virion free pathway. We found thatpDC can also sense infection with classical swine fever virus (CSFV),another member <strong>of</strong> the Flaviviridae, by direct contact with infected cells,a process that is independent <strong>of</strong> virus particles. This process is much moreefficient in terms <strong>of</strong> interferon alpha induction when compared to directstimulation by virus particles. By employment <strong>of</strong> virus replicon particlesor infectious RNA that can replicate but not form de novo virions, a transfer<strong>of</strong> virus from the donor cell to the pDC was excluded. Activation <strong>of</strong>pDC by infected cells is mediated by a contact dependent RNA transfer topDC, which is sensitive to a TLR7 inhibitor. Interestingly, the Erns protein<strong>of</strong> CSFV does efficiently prevent this process, which requires intactribonuclease function <strong>of</strong> Erns in intracellular compartments. The presentstudy underlines the importance <strong>of</strong> pDC activation by infected cells andidentifies a novel pathway <strong>of</strong> viral escape from the interferon system.ORAL COMMUNICATIONSREF 001Activation <strong>of</strong> RIG I by incoming RNA virus nucleocapsids containinga5 ′ triphosphorylated genomeMichaela WEBER 1 , Ali GAWANBACHT 2 , Matthias HABJAN 2 ,Andreas RANG 3 , Christoph BORNER 4,5 , Anna Mareike SCHMIDT 2,5 ,Sophie VEITINGER 6 , Ralf JACOB 6 , Stéphanie DEVIGNOT 1 , GeorgKOCHS 2 , Adolfo GARCÍA SASTRE 7,8,9 , Friedemann WEBER 1,2,51 Philipps University Marburg, Institute for <strong>Virology</strong>, Marburg,GERMANY; 2 University Freiburg, Department <strong>of</strong> <strong>Virology</strong>, Freiburg,GERMANY; 3 University Hospital Charité, Institute <strong>of</strong> <strong>Virology</strong>, Berlin,GERMANY; 4 University Freiburg, Institute <strong>of</strong> Molecular Medicine,Freiburg, GERMANY; 5 Albert Ludwigs University Freiburg, Centre forBiological Signalling Studies (BIOSS), Freiburg, GERMANY; 6 PhilippsUniversity Marburg, Department <strong>of</strong> Cell Biology and Cell Pathology,Marburg, GERMANY; 7 Mount Sinai School <strong>of</strong> Medicine, Department <strong>of</strong>Microbiology, New York, USA; 8 Mount Sinai School <strong>of</strong> Medicine, Department<strong>of</strong> Medicine, Division <strong>of</strong> Infectious Diseases, New York, USA; 9 MountSinai School <strong>of</strong> Medicine, Global Health and Emerging Pathogens Institute,New York, USAREF 003Integrins synergize with TLRs to initiate a specific branch <strong>of</strong> the innateresponse to herpes simplex virusGabriella CAMPADELLI FIUME, Tatiana GIANNIDepartment <strong>of</strong> Experimental Diagnostic and Specialty Medicine, AlmaMater Studiorum – University <strong>of</strong> Bologna, Bologna, ITALYIntegrins are exquisite signaling molecules that regulate a number <strong>of</strong> cellularprocesses. They are also very popular among viruses as cellularreceptors. We have discovered that the av3 integrin serves the additionalfunction <strong>of</strong> sensor <strong>of</strong> herpes simplex virus (HSV) and initiator <strong>of</strong> abranch <strong>of</strong> the innate response which culminates in the secretion <strong>of</strong> a specificset <strong>of</strong> cytokines, including IFNa and . This function is exerted throughinteraction and synergy with TLR2.Here we report that av3 integrin is not the only one integrin that servesthe function <strong>of</strong> innate response sensor. We found that av6 and av8 canserve as HSV receptors, each independently <strong>of</strong> the other, via interactionwith gH/gL. av6 but not av8 integrins can activate specific branches <strong>of</strong>the innate response. Further yet, integrins synergize also with TLR4. Thesignalling activity which culminates in the innate response involves theVi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013S39
5 th <strong>European</strong> <strong>Congress</strong> <strong>of</strong> <strong>Virology</strong>phosphorylation <strong>of</strong> specific thyrosine residues in the cytoplamic tail <strong>of</strong> integrins. Remarkably, the synergistic integrin TLR innate activity is seenin response not only to HSV, but also bacterial components.Our studies support the following conclusions. (i) Integrins constitute anovel class <strong>of</strong> pattern recognition receptors. (ii) Inasmuch as integrinsserve as receptors for HSV entry, they couple virus entry with initiation <strong>of</strong>a branch <strong>of</strong> the innate response, and thus ensure activation <strong>of</strong> host defencemechanisms. (i) The role <strong>of</strong> integrins as pathogens’ sensors is not restrictedto HSV, but is broader.REF 004Severe acute respiratory syndrome virus with E protein deleted wasattenuated because E protein was responsible for the induction <strong>of</strong> aninflammatory response mediated by NF KB activationLuis ENJUANES, Jose L. NIETO TORRES, Jose M. JIMÉNEZGUARDEÑO, Jose A. REGLA NAVAS, Carlos CASTAÑO, RaulFERNANDEZ, Marta L. DEDIEGODepartment <strong>of</strong> Molecular and Cell Biology, National Center <strong>of</strong> Biotechnology(CNB CSIC), Darwin 3, Madrid, SPAINDeletion <strong>of</strong> E gene from SARS CoV led to an attenuated virus (SARS CoVE). Stress response and unfolded protein response genes were upregulatedin cells infected by SARS CoV E in relation with the infection bySARS CoV with E protein. The expression <strong>of</strong> proinflammatory cytokineswas reduced in lungs <strong>of</strong> mice infected with a mouse adapted SARS CoVMA15 E compared to lungs infected with wt virus. The induction <strong>of</strong>virus induced inflammatory responses may be mediated by the activation<strong>of</strong> five signaling pathways (IRF3/7, ATF 2/Jun, AP 1, NF KB, and NFAT), but in infections by SARS CoV with and without E protein the onlypathway differentially activated was NF KB. Interestingly, the addition <strong>of</strong>an inhibitor <strong>of</strong> NF KB led to a reduced inflammatory response after SARSCoV infection, significantly inhibiting the proinflammatory cytokine response.A reduction in neutrophil migration to sites <strong>of</strong> lung inflammationwas observed in mice infected with SARS CoV MA15 E, what probablycontributed to the lower degree <strong>of</strong> inflammation detected and to SARSCoV E attenuation. The mutant SARS CoV missing E protein providedprotection against challenge with homologous and heterologous pathogenicSARS CoVs in hamsters and transgenic mice. Furthermore, SARSCoV MA15 E provided complete long term protection against a virulentmouse adapted SARS CoV in both young and old Balb/c mice. These dataindicate that SARS CoV E is a very promising vaccine candidate andthat inhibitors <strong>of</strong> NF KB may protect against SARS CoV infection.REF 005A reverse genetics approach to study the determinants for dsRNAbinding and PKR inhibition in the NS1 protein <strong>of</strong> influenza A virusKristina L. SCHIERHORN 1 , Katrin HOEGNER 2 , JuliaDZIECIOLOWSKI 3 , Susanne HEROLD 2 , Stephan PLESCHKA 3 ,Thorsten WOLFF 11 Robert Koch Institute, Influenza and other respiratory viruses, Berlin,GERMANY; 2 Justus Liebig University Gieβen, Department for InternalMedicine II, Section <strong>of</strong> Infectious Diseases, Gieβen, GERMANY; 3 JustusLiebig University, Institute for Medical <strong>Virology</strong>, Gieβen, GERMANYThe non structural protein 1 (NS1) <strong>of</strong> influenza viruses functions in inhibitingthe type I IFN mediated antiviral state in infected cells. WhileNS1 proteins <strong>of</strong> influenza A and B viruses (A/NS1 and B/NS1) haveonly 20% sequence identity, they have a conserved N terminal dsRNAbinding domain (RBD) and share functions as inhibition <strong>of</strong> the antiviralkinase PKR. We have previously shown that distinct basic amino acidsin the RBD <strong>of</strong> B/NS1 are required for dsRNA binding and inhibition <strong>of</strong>PKR. In contrast, A/NS1 has been suggested to silence PKR by a physicalinteraction involving a region outside the RBD. To evaluate whetherthe two influenza virus types in fact inhibit PKR by different means, weconducted a systematic analysis <strong>of</strong> the RBD <strong>of</strong> A/NS1 using reverse genetics.Among a panel <strong>of</strong> constructed mutants we identified 3 NS1 proteinswith single basic amino acid exchanges eliminating dsRNA binding. Two<strong>of</strong> the corresponding mutant viruses showed a 10 fold reduction in viralreplication, possibly due to strong IFN induction. The third mutant viruswas severely attenuated for replication by 4 logs, which was paralleledby strong activation <strong>of</strong> PKR, but very low IFN secretion. Significantly,replication <strong>of</strong> this mutant virus was largely rescued on PKR knock downcells illustrating the strong impact <strong>of</strong> PKR on viral propagation. Thus, thisstudy highlights the crucial role <strong>of</strong> the RBD <strong>of</strong> A/NS1 for PKR inhibitionand viral replication. Moreover, we suggest that PKR has a major role inrestricting influenza virus propagation among the more than 400 knowntype I IFN stimulated factors.REF 006The matrix protein <strong>of</strong> rabies virus binds to RelAp43 to suppress NFKB dependent gene expression related to innate immunityYoucef BEN KHALIFA 1 , Sophie LUCO 1,2 , Mehdi ARCHAMBAUD 2 ,Olivier DELMAS 1 , Jonathan GRIMES 3 , Hervé BOURHY 11 Institut Pasteur, Unité Dynamique des Lyssavirus et Adaptation à l’hôte,Paris, France; 2 Université Paris Diderot, Sorbonne Paris Cité, CellulePasteur, Paris, France; 3 Division <strong>of</strong> Structural Biology, Welcome TrustCenter for human Genetics, University <strong>of</strong> Oxford, Oxford, ENGLANDThe activation <strong>of</strong> expression <strong>of</strong> genes involved in innate immune responseis controlled by the activity <strong>of</strong> transcription factors such as the proteins <strong>of</strong>the NF KB family. Recently, we identified a sixth member <strong>of</strong> this family,RelAp43, which is involved in the activation <strong>of</strong> INF transcription duringviral infection (Luco et al., PLoS Pathog 2012). Since, we showed that thematrix (M) protein <strong>of</strong> wild isolates <strong>of</strong> rabies virus such as Tha (M Tha) isable to interact with RelAp43 and to efficiently suppress NF kB dependentreporter gene expression, in response to activation by tumor necrosis factor(TNF), in contrast with the vaccine strain SAD. Co immunoprecipitationassays revealed that the central part <strong>of</strong> M Tha is required for this interaction.Comparison <strong>of</strong> the corresponding amino acid sequence <strong>of</strong> the M Tha andM SAD, identified 4 differences, two <strong>of</strong> which induce the loss <strong>of</strong> binding<strong>of</strong> M Tha to RelAp43 but are not sufficient to restore the NF KB dependentreporter gene expression. To fully restore this effect, additional mutationsare required. Moreover, we selected a subset <strong>of</strong> genes involved in antiviralresponse and we identified four genes as particularly down regulated by MTha compared to M SAD: CYCLD, NFKB1, STAT1 and TRIM25. Finally,we used an approach that relies on small interfering RNA <strong>of</strong> RelAp43 in thepresence <strong>of</strong> M Tha or M SAD to study the modulation <strong>of</strong> genes involved ininnate immunity and in NF KB signaling. Thus, RABV M protein appearsas a potent viral immune modulatory factor that prevents NF KB dependentgene expression by fixation <strong>of</strong> RelAp43.S40 Vi<strong>rologie</strong>, Vol 17, supplément 2, septembre 2013
- Page 3 and 4: Contents5 th European Congress of V
- Page 5 and 6: i r o l o g i eList of Keynote Spea
- Page 7 and 8: i r o l o g i eList of Chairpersons
- Page 9 and 10: i r o l o g i eWelcomeWelcome to th
- Page 11 and 12: 5 th European Congress of VirologyY
- Page 13 and 14: i r o l o g i eExhibitorsThe indust
- Page 15: i r o l o g i eFacilities for the 5
- Page 18 and 19: i r o l o g i eGeneral Information
- Page 20 and 21: PROGRAMME AT A GLANCEWednesday 11th
- Page 22 and 23: 5 th European Congress of VirologyW
- Page 24 and 25: 5 th European Congress of VirologyW
- Page 26 and 27: 5 th European Congress of VirologyW
- Page 28 and 29: 5 th European Congress of VirologyW
- Page 30 and 31: 5 th European Congress of VirologyW
- Page 32 and 33: Scientific Programme -Saturday 14 t
- Page 34 and 35: 5 th European Congress of Virology1
- Page 36 and 37: 5 th European Congress of VirologyW
- Page 38 and 39: 5 th European Congress of VirologyW
- Page 42 and 43: 5 th European Congress of VirologyW
- Page 44 and 45: 5 th European Congress of VirologyW
- Page 46 and 47: 5 th European Congress of VirologyW
- Page 48 and 49: 5 th European Congress of VirologyT
- Page 50 and 51: 5 th European Congress of VirologyT
- Page 52 and 53: 5 th European Congress of VirologyT
- Page 54 and 55: 5 th European Congress of VirologyR
- Page 56 and 57: 5 th European Congress of VirologyR
- Page 58 and 59: 5 th European Congress of Virologyw
- Page 60 and 61: 5 th European Congress of VirologyT
- Page 62 and 63: 5 th European Congress of VirologyR
- Page 64 and 65: 5 th European Congress of Virologyt
- Page 66 and 67: 5 th European Congress of VirologyR
- Page 68 and 69: 5 th European Congress of VirologyT
- Page 70 and 71: 5 th European Congress of VirologyA
- Page 72 and 73: 5 th European Congress of Virologyp
- Page 74 and 75: 5 th European Congress of VirologyR
- Page 76 and 77: 5 th European Congress of VirologyF
- Page 78 and 79: 5 th European Congress of VirologyF
- Page 80 and 81: 5 th European Congress of Virologyc
- Page 82 and 83: 5 th European Congress of VirologyF
- Page 84 and 85: 5 th European Congress of VirologyF
- Page 86 and 87: 5 th European Congress of Virologyt
- Page 88 and 89: 5 th European Congress of VirologyH
- Page 90 and 91:
5 th European Congress of VirologyF
- Page 92 and 93:
5 th European Congress of VirologyR
- Page 94 and 95:
5 th European Congress of VirologyR
- Page 96 and 97:
5 th European Congress of VirologyS
- Page 98 and 99:
5 th European Congress of VirologyS
- Page 100 and 101:
5 th European Congress of VirologyS
- Page 102 and 103:
5 th European Congress of VirologyS
- Page 104 and 105:
5 th European Congress of VirologyA
- Page 106 and 107:
5 th European Congress of Virology1
- Page 108 and 109:
5 th European Congress of Virology1
- Page 110 and 111:
5 th European Congress of VirologyS
- Page 112 and 113:
5 th European Congress of VirologyS
- Page 114 and 115:
5 th European Congress of VirologyS
- Page 116 and 117:
5 th European Congress of VirologyS
- Page 118 and 119:
Virologie 2013, 17 (supplément 2)
- Page 120 and 121:
5 th European Congress of VirologyA
- Page 122 and 123:
5 th European Congress of Virology0
- Page 124 and 125:
5 th European Congress of Virology0
- Page 126 and 127:
5 th European Congress of VirologyH
- Page 128 and 129:
5 th European Congress of Virologys
- Page 130 and 131:
5 th European Congress of Virology0
- Page 132 and 133:
5 th European Congress of Virologyf
- Page 134 and 135:
5 th European Congress of VirologyE
- Page 136 and 137:
5 th European Congress of Virologyt
- Page 138 and 139:
5 th European Congress of VirologyA
- Page 140 and 141:
5 th European Congress of Virologyp
- Page 142 and 143:
5 th European Congress of Virology0
- Page 144 and 145:
5 th European Congress of Virologyi
- Page 146 and 147:
5 th European Congress of Virologyr
- Page 148 and 149:
5 th European Congress of Virologyi
- Page 150 and 151:
5 th European Congress of Virologyp
- Page 152 and 153:
5 th European Congress of Virology3
- Page 154 and 155:
5 th European Congress of VirologyR
- Page 156 and 157:
5 th European Congress of Virology0
- Page 158 and 159:
5 th European Congress of Virologyt
- Page 160 and 161:
5 th European Congress of VirologyB
- Page 162 and 163:
5 th European Congress of Virologyr
- Page 164 and 165:
5 th European Congress of VirologyR
- Page 166 and 167:
5 th European Congress of Virologyi
- Page 168 and 169:
5 th European Congress of VirologyI
- Page 170 and 171:
5 th European Congress of Virologyf
- Page 172 and 173:
5 th European Congress of Virologya
- Page 174 and 175:
5 th European Congress of VirologyS
- Page 176 and 177:
5 th European Congress of Virology1
- Page 178 and 179:
5 th European Congress of Virologyt
- Page 180 and 181:
5 th European Congress of VirologyV
- Page 182 and 183:
5 th European Congress of Virologyc
- Page 184 and 185:
5 th European Congress of Virologyw
- Page 186 and 187:
5 th European Congress of Virologyt
- Page 188 and 189:
5 th European Congress of Virologya
- Page 190 and 191:
5 th European Congress of VirologyA
- Page 192 and 193:
5 th European Congress of Virologyn
- Page 194 and 195:
5 th European Congress of Virologyi
- Page 196 and 197:
5 th European Congress of Virologyw
- Page 198 and 199:
5 th European Congress of VirologyT
- Page 200 and 201:
5 th European Congress of Virology(
- Page 202 and 203:
5 th European Congress of Virologya
- Page 204 and 205:
5 th European Congress of Virology1
- Page 206 and 207:
5 th European Congress of Virologyo
- Page 208 and 209:
5 th European Congress of VirologyI
- Page 210 and 211:
5 th European Congress of VirologyR
- Page 212 and 213:
5 th European Congress of Virologyw
- Page 214 and 215:
5 th European Congress of Virologyt
- Page 216 and 217:
5 th European Congress of Virologya
- Page 218 and 219:
5 th European Congress of Virologyp
- Page 220 and 221:
5 th European Congress of Virologya
- Page 222 and 223:
5 th European Congress of Virology(
- Page 224 and 225:
5 th European Congress of Virologyt
- Page 226 and 227:
5 th European Congress of Virologyn
- Page 228 and 229:
5 th European Congress of Virologyi
- Page 230 and 231:
5 th European Congress of Virologyo
- Page 232 and 233:
5 th European Congress of Virology2
- Page 234 and 235:
5 th European Congress of VirologyR
- Page 236 and 237:
5 th European Congress of Virology7
- Page 238 and 239:
5 th European Congress of VirologyR
- Page 240 and 241:
5 th European Congress of VirologyR
- Page 242 and 243:
5 th European Congress of Virologya
- Page 244 and 245:
5 th European Congress of Virologyc
- Page 246 and 247:
5 th European Congress of Virologya
- Page 248 and 249:
5 th European Congress of Virologyh
- Page 250 and 251:
5 th European Congress of Virology6
- Page 252 and 253:
5 th European Congress of VirologyC
- Page 254 and 255:
5 th European Congress of VirologyM
- Page 256 and 257:
5 th European Congress of Virologyi
- Page 258 and 259:
5 th European Congress of Virology2
- Page 260 and 261:
5 th European Congress of Virologyf
- Page 262 and 263:
5 th European Congress of VirologyR
- Page 264 and 265:
5 th European Congress of Virologyw
- Page 266 and 267:
5 th European Congress of VirologyM
- Page 268 and 269:
5 th European Congress of VirologyI
- Page 270 and 271:
5 th European Congress of Virologyp
- Page 272 and 273:
5 th European Congress of Virologyu
- Page 274 and 275:
5 th European Congress of VirologyO
- Page 276 and 277:
5 th European Congress of Virologys
- Page 278 and 279:
5 th European Congress of Virology2
- Page 280 and 281:
5 th European Congress of Virologyf
- Page 282 and 283:
5 th European Congress of Virology2
- Page 284 and 285:
5 th European Congress of VirologyA
- Page 286 and 287:
5 th European Congress of VirologyI
- Page 288 and 289:
5 th European Congress of VirologyB
- Page 290 and 291:
5 th European Congress of VirologyD
- Page 292 and 293:
5 th European Congress of VirologyG
- Page 294 and 295:
5 th European Congress of VirologyJ
- Page 296 and 297:
5 th European Congress of VirologyL
- Page 298 and 299:
5 th European Congress of VirologyN
- Page 300 and 301:
5 th European Congress of VirologyR
- Page 302 and 303:
5 th European Congress of VirologyS
- Page 304 and 305:
5 th European Congress of VirologyW